Quarterly Report 3, June 2016

Dear Shareholders

It was with great pride and humility that I took over the role of CEO of Diamyd Medical nearly two months ago. This has been an intense period and I recently returned from the American Diabetes Association’s (ADA) 76th Scientific Sessions in New Orleans, the world’s largest diabetes conference, with more than 16,000 delegates. The principal message for the type 1 diabetes field was clear: combination therapy and innovative studies are the key to preventing and curing the disease. Government players in the US are showing increasing...

Diamyd Medical is at the very leading edge of the type 1 diabetes field, with clinical studies that are in line with what leading experts see as the future of this area.
Ulf Hannelius, President and CEO

Annual Report

  November 05, 2015


We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies


The Share

The Diamyd Medical share is traded on NASDAQ Stockholm First North (ticker : DMYD B).

About First North

First North is an alternative marketplace operated by an exchange within the NASDAQ OMX group. Companies on First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on First North may therefore be higher than investing in a company on the main market. All companies with shares traded on First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at First North

Remium Nordic AB, Kungsgatan 12-14, 111 35 Stockholm, 08-454 32 00, www.remium.com


 Dates for financial information and other events
October 12, 2016
Financial Statement
Financial Statement 2015/2016
November 03, 2016
Annual Report
Annual Report 2015/2016
November 07, 2016
BIO-Europe® 2016
BIO-Europe® is Europe’s largest partnering conference serving the global biotechnology industry.
November 24, 2016
Annual General Meeting
The Annual General Meeting will be held at 3:00 pm on November 24, 2016, at Hotell Kung Carl, Birger Jarlsgatan 21 in Stockholm, Sweden.

Ten largest shareholders as of June 30, 2016

ShareholderA SharesB SharesShare Capital (%)Votes (%)
Essen-Möller, Anders 1 278 112 3 666 521 16.77 40.12
Avanza Pension 4 128 000 14.00 10.06
Lindkvist, Bertil 3 815 040 12.94 9.31
Nordnet Pensionsförsäkring AB 880 878 2.98 2.15
Robur Försäkring 590 246 2.00 1.44
Protein Sciences Corporation 400 000 1.36 0.98
Waldolf, Rolf Eric 298 666 1.01 0.73
Försäkrings AB Skandia 273 098 0.93 0.67
Handelsbanken Liv 242 765 0.82 0.59
Bohlin, Lennart 233 998 0.79 0.57
Remaining shareholders 13 685 238 46.40 33.38
Total 1 278 112 28 214 450 100.00 100.00